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ABSTRACT
Our lab established that moderate ethanol preconditioning (MEP) for 6 days
blocked the Aβ 25-35 toxicity in cerebellar mixed cell cultures and It has been shown that
MEP cause the up regulation of the pre-survival enzymes such as proxiredoxin2 (PRX2),
which suggests MEP can activate the cell survival pathways against upcoming toxins.
This study was performed to verify the possible combinatory effect of ethanol and
resveratrol against Aβ 25-35 toxicity. Both ethanol and resveratrol sub-protective
concentrations were detected against Aβ 25-35 in cerebellar mixed cell cultures. The
combination of sub-protective levels of ethanol and resveratrol showed the significantly
reduction in number of Aβ 25-35 toxicity compare to preconditioning with ethanol or
resveratrol alone. The western blot analysis revealed that proxiredoxin2 levels were
increased significantly in preconditioned cell cultures with combined sub-protective level
of ethanol and resveratrol.
Combination of sub-protective levels of ethanol and resveratrol showed
synergistic protection against Aβ 25-35 toxicity.
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CHAPTER ONE
INTRODUCTION

i. Alcohol Toxicity and Preconditioning

There are strong correlation between heavy alcohol consumption and increased
risk of developing cardiovascular disease, chronic pancreatitis, alcoholic liver disease,
and cancer. Risk of damage to the central nervous system and peripheral nervous
system is also increased by chronic alcohol abuse. However alcohol consumption and
mortality show a J-shaped relationship, which means that in moving from alcohol
abstinence to heavy drinking the rate of mortality is lower in light to moderate consumers
than abstainers while heavy drinkers have higher rates of mortality from a number of
causes (1).
Thus, while excessive alcohol consumption has been linked to a number of
serious health and social problems, moderate alcohol consumption has been associated
with some health benefits. Because the consumption of alcohol can be viewed as a
“double-edged sword,”

1
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Individual decisions regarding alcohol use should take into consideration
scientific evidence regarding potential health benefits and risks as well as personal and
family histories of health problems and addictions (2).

Definitions
Standard alcoholic drink

A standard alcoholic drink contains approximately 14 grams of alcohol, which is
equivalent to 12 fluid ounces of beer, 5 fluid ounces of wine, 3.5 fluid ounces of fortified
wine (e.g., sherry or port), or 1.5 fluid ounces of liquor (distilled spirits).
Moderate Alcohol Consumption (as defined by the U.S. Department of Agriculture (3))
•

Men: No more than two standard alcoholic drinks/day

•

Women: No more than one standard alcoholic drink/day*

•

Adults over 65: No more than one standard alcoholic drink/day#

Heavy Alcohol Consumption

•

Men: 15 or more standard alcoholic drinks/week or 5 or more alcoholic

drinks on any given occasion
•

Women: 8 or more standard alcoholic drinks/week or 4 or more alcoholic

drinks on any given occasion*
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•

Adults over 65: 8 or more standard alcoholic drinks/week or 4 or more

alcoholic drinks on any given occasion#
On average, women absorb and metabolize alcohol differently than men. In
general, women have less body water than men of similar body weight, so after drinking
equivalent amounts of alcohol women achieve higher blood alcohol concentrations (4).
Women appear to be more sensitive to side health effects of heavy drinking than men. So,
definitions of “moderate” or “heavy” drinking apparently are lower for women than men.
Age-associated decreases in lean body mass may result in decreased total body
water and higher blood alcohol concentrations in older adults compared to younger adults
after drinking equivalent amounts of alcohol (5).

Moderate Alcohol Consumption Benefit for Cardiovascular Disease and Coronary
Heart Disease

More than 60 epidemiological studies have shown a significant reduction in the
risk of coronary heart disease (CHD) with moderate alcohol consumption (6). Recent
data from two large prospective cohort studies in the U.S. proposed that the amount of
CHD risk reduction related with moderate alcohol consumption might be closer to 30%.
In a 12-year study of more than 38,000 male health professionals, those who consumed
alcohol at least 3-4 times weekly had a risk of myocardial infarction (heart attack) that
was 32% lower than men who drank alcohol less than once weekly (7). When the results
of 28 prospective cohort studies were combined in a meta-analysis, adults who consumed
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an average of 25 grams/day of alcohol (the amount in two standard alcoholic drinks) had
a risk of CHD that was 20% lower than adults who did not consume alcohol (8).
Similarly, in a 20-year study of more than 120,000 men and women, those who reported
consuming 1-2 alcoholic drinks daily had a risk of death from CHD that was 30% lower
than those who did not drink alcohol (9). Coronary heart disease is a major cause of heart
failure. A prospective study in a cohort of126, 236 men and women and another in a
cohort of 21, 601 men found that moderate alcohol intake might be inversely associated
with increase of heart failure rate, especially heart disease related to CHD (10-11).
The formation of cholesterol plaque in the arteries (atherosclerosis), vascular
inflammation, and platelet aggregation are characteristic for development of CHD (12).
One of the roles of HDL is to carry cholesterol from tissues, such as arterial walls, back
to the liver for elimination or recycling. Basically, higher levels of HDL-cholesterol lead
to reductions in CHD risk (13). Most of randomized trials have consistently shown that
moderate alcohol consumption significantly increases HDL-cholesterol levels that inhibit
coagulation or enhance the dissolution of clots (14). Moderate alcohol intakes has shown
an anti-inflammatory effect by reducing the serum levels of C-reactive protein (CRP), a
systemic inflammation biomarker and sensitive predictor of CHD risk, compare to
abstainers (15-18). Also, moderate alcohol consumption improves insulin sensitivity,
lowers serum triglycerides, and reduces abdominal obesity (19).
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Red wine reduces CHD risk more than other alcoholic beverages.

Moderate consumption of wine, beer, and liquor has all been shown significant
reductions in CHD risk. However wine is rich in phenolic compounds like resveratrol that
have been found to have antioxidant, anti-inflammatory, and potentially anti-atherogenic
properties in the in vitro experiments and in some in vivo models of atherosclerosis (20).
The “French Paradox”—the observation that mortality from CHD is relatively low in
France despite relatively high levels of dietary saturated fat and cigarette smoking—led
to the idea that regular consumption of red wine might provide additional protection from
CHD (21,22). Although moderate alcohol consumption consistently has been shown 2030% reductions in CHD risk, nonalcoholic compounds abundant in red wine have not
shown any additional CHD risk reduction. Other prospective studies found that wine
drinkers were at lower risk of CHD than beer or liquor drinkers (9,27,28), others found
no difference (8,29,30). Socioeconomic and lifestyle differences between people who
prefer wine and those who prefer beer or liquor may explain part of the additional benefit
observed in some studies. Several studies have demonstrated that wine drinkers have
higher incomes, have more formal education, smoke less, and eat more fruits and
vegetables and less saturated fat than people who prefer other alcoholic beverages (3133).
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Ischemic Stroke

A stroke, also known as a cerebrovascular accident (CVA), is the rapid loss
of brain functions due to disturbance in the blood supply to the brain. This can be due
to ischemia (Lack of blood flow) caused by blockage or a hemorrhage (leakage of blood).
83% of strokes are classified as ischemic strokes (34). Moderate alcohol consumption has
been associated with a reduced risk of ischemic stroke but not hemorrhagic stroke in a
number of observational studies (31-34). Combined meta-analysis results of 19
prospective cohort studies and 16 case-control studies of moderate alcohol consumption
and the risk of stroke has shown a significant reduction in the risk of ischemic
stroke (35). Overall, those who consumed one or two drinks daily had a 28% lower risk
of ischemic stroke than those who did not consume alcohol.

Moderate alcohol and Dementia and Cognitive Decline

Although previous studies of alcohol consumption and the risk of dementia have
shown conflicting results (49,50), two prospective studies that observed older adults
without dementia for six years found that those who reported moderate alcohol intakes
were significantly less likely to develop dementia than whose abstaining from alcohol
(51,52). A recent prospective study of 11,102 women reported that moderate alcohol
consumption was associated with improved cognitive function and less cognitive decline
over a two-year period, compared to nondrinkers (53). Two epidemiological studies have
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used MRI to examine relationships between alcohol intake and subclinical abnormalities
in the brains of older adults. Although one study found that infarctions were less frequent
in the brains of those reporting moderate alcohol intake compared to those who abstained
from alcohol (54), another study found no relationship between alcohol intake and the
presence of infarction (54). In contrast, measures of brain atrophy, a characteristic of
Alzheimer’s disease and alcoholic dementia, were lowest in those who abstained from
alcohol and increased with alcohol consumption in both studies (54-55).

ii. Resveratrol

Resveratrol (3,4', 5-trihydroxystilbene) is a member of a class of polyphenolic
compounds called stilbenes (56). Resveratrol and other stilbenes are produced in some
types of plants is in response to stress, injury, fungal or bacterial infection, or ultraviolet
(UV) radiation (57). Scientists became interested in exploring potential health benefits of
resveratrol in 1992 when its presence was first reported in red wine (59) leading to the
hypothesis that, resveratrol might help explain the “French Paradox”. The “French
Paradox”—the observation that mortality from coronary heart disease is relatively low in
France despite relatively high levels of dietary saturated fat and cigarette smoking—led
to the idea that regular consumption of red wine might provide additional protection from
cardiovascular disease (73, 74).

8
Metabolism and Bioavailability

Although trans-resveratrol seems to be well absorbed by humans when taken
orally, its bioavailability is low due to its rapid metabolism and elimination (61, 62).
Results of another study suggested that the bioavailability of resveratrol from grape juice,
which contains mostly glucosides of resveratrol, may be even lower than transresveratrol (63).
Resveratrol metabolites are primarily detected upon oral exposure to transresveratrol. In one experiment, six healthy men and women took an oral dose of 25 mg
of trans-resveratrol; only traces of the un-metabolized resveratrol were detected in
plasma (blood). Plasma concentrations of resveratrol and metabolites peaked around 60
minutes later at concentrations around 2 micromoles/liter (491 micrograms/liter) (61).

Biological Activities
Direct Antioxidant Activity

In vitro, resveratrol effectively scavenges (neutralizes) free radicals and
other oxidants (64) and inhibits low-density lipoprotein (LDL) oxidation (65, 66).
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Induction of Apoptosis in Cancer Cells

Unlike normal cells, cancer cells proliferate rapidly and are resistant to cell death
signals that initiate apoptosis. Resveratrol has been found to inhibit the proliferation of a
variety of human cancer cell lines, including those from breast, prostate, stomach, colon,
pancreatic, and thyroid cancers Resveratrol has been found to inhibit proliferation and
induce apoptosis in a number of cancer cell lines [reviewed in (57,67)]. In animal models,
oral administration of resveratrol inhibited the development of esophageal (20), intestinal
(76), and mammary (breast) cancer (67,77). Few studies have shown that oral resveratrol
protects against colon cancer development in rats induced by the carcinogen, (78, 79, 80).

Inhibition of Vascular Cell Adhesion Molecule Expression

Inflammation is one of the earliest events in the development of atherosclerosis
and begins with adhesion of white blood cells from the blood to the arterial wall by
vascular cell adhesion molecules (68). Resveratrol has been found to inhibit the
expression of adhesion molecules in cultured endothelial cells (69, 70).
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Inhibition of Platelet Aggregation

Platelet aggregation leads to formation of blood clot can result in myocardial
infarction or stroke, respectively. Resveratrol has been found to inhibit platelet
aggregation in vitro (71, 72).

Activation of autophagy in parkinsonic cells

Excessive misfolded proteins and/or dysfunctional mitochondria, which may
cause energy deficiency, have been implicated in the etiopathogenisis of Parkinson’s
disease (PD). Enhanced clearance of misfolded proteins or injured mitochondria via
autophagy has been reported to in resveratrol treated cell cultures. Resveratrol has
neuroprotective role in PD models (93).
The neuroprotective effects of resveratrol against Aβ toxicity has been shown in rat
hippocampal cells cultures via protein kinase C pathway (92).

Inhibition of atherosclerosis

Resveratrol and other poyphenolic compounds in the red wine, which have shown
antioxidant, anti-inflammatory, and anti-atherogenic effects in vitro and in some animal
models of atherosclerosis (95).
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Alcoholic Encephalopathy

Alcoholic encephalopathy is one of the hallmarks of neurinflammation results
from chronic and excessive consumption of alcohol due to increased oxidative nitrosative
stress and activation of inflammatory cascade, which leads to neural apoptosis in cortex
and hypothalamus.

Neuroprotection

Brief resveratrol pretreatment conferred neuroprotection against cerebral ischemia
via SIRT activation. This neuroprotective effect produced by resveratrol was similar to
ischemic preconditioning –induced neuroprotection, which protects against lethal
ischemic insults in brain and other organ system (94).

Longevity

In yeast, caloric restriction stimulates the activity of an enzyme known as
Sir2 (81), and also increased the activity of the homologous human enzyme (Sirt1) (60).
Treating the yeast with resveratrol increased Sir2 activity in the absence of
caloric restriction and the replicative lifespan of yeast by 70% (60). A recent study
reported that resveratrol extended lifespan of mice on a high-calorie diet such that their
lifespan was similar to that of mice fed a standard diet (82). A recent aging study in mice
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found that a low dose of dietary resveratrol changed gene expression in heart, brain, and
skeletal muscle similar to that induced by caloric restriction Like caloric restriction,
resveratrol also blunted the age-related decline in heart function in this study. Clinical
trials will be needed to determine if these findings are relevant to humans (83).

Food Sources

Resveratrol is found in grapes, wine, grape juice, peanuts, and berries such as
blueberries, bilberries, and cranberries (84, 85, 86). In grapes, resveratrol is found only in
the skins (87). The amount of resveratrol in grape skins varies with the grape cultivar, its
geographic origin, and exposure to fungal infection (88). The amount of fermentation
time a wine spends in contact with grape skins is an important determinant of its
resveratrol content. Consequently, white and rosé wines generally contain less resveratrol
than red wines (59). Red or purple grape juices may also be good sources of resveratrol
(58). The predominant form of resveratrol in grapes and grape juice is trans-resveratrol
glucoside (trans-piceid), but wines also contain significant amounts of resveratrol
aglycones, thought to be the result of sugar cleavage during fermentation (84).
The total resveratrol content of some beverages and foods are listed in the tables
below. These values should be considered approximate since the resveratrol content of
foods and beverages can vary considerably.
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Total Resveratrol Content of Wines and Grape Juice (58, 85, 86)
Total resveratrol

Total resveratrol in a

Beverage
(mg/liter)

(mg)

White wines (Spanish)

0.05-1.80

0.01-0.27

Rosé wines (Spanish)

0.43-3.52

0.06-0.53

Red wines (Spanish)

1.92-12.59

0.29-1.89

Red wines (global)

1.98-7.13

0.30-1.07

1.14-8.69

0.17-1.30

Red grape juice
(Spanish)

Table 1: Total Resveratrol Content of Wines, Grape Juice

5-oz glass
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Total Resveratrol Content of Selected Foods (84, 85, 86)
Food

Serving

Total resveratrol (mg)

Peanuts (raw)

1 cup (146 g)

0.01-0.26

Peanuts (boiled)

1 cup (180 g)

0.32-1.28

Peanut butter

1 cup (258 g)

0.04-0.13

Red grapes

1 cup (160 g)

0.24-1.25

Table 2: Total Resveratrol Content of Selected Foods
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iii. Alzheimer Disease

The burden of Alzheimer Disease

According to the Alzheimer’s Association’s Alzheimer’s Disease Facts &Figures
2010, there are as many as 5.3 million Americans living with Alzheimer disease (AD)
and every 70 seconds someone in America develops AD. In 2010, there were half a
million new cases of AD. The Alzheimer ‘s Association estimates that total U.S.
payments for health and long term care service for people with AD will amount to $172
billion in 2010. Nearly 11 million U.S. family members and other unpaid caregivers
provided 12.5 billion hours of care for people with Alzheimer’s and other dementias,
valued at $144 billion. The total estimated worldwide costs of dementia are $640 billion
in 2010. In the World Alzheimer Report 2009, estimated that there are 35.6 million
people living with dementia worldwide, and this will increase to 65.7 million by 2030.

Alzheimer Disease Pathology

Alzheimer's disease is characterized by loss of neurons and synapses in the cerebral
cortex and certain subcortical regions. Amyloid plaques and neurofibrillary tangles are clearly
visible by microscopy in brains of those afflicted by AD (90). Plaques are dense deposits
of amyloid beta peptide and cellular material outside and around neurons. Neurofibrillary
tangles are aggregates of the microtubule-associated protein tau, which have become
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hyperphosphorylated and which accumulate inside the cells themselves (91). Sporadic AD,
constituting the most of AD cases with a late age of onset (65 years and older)(92); In contrast,
familial AD constitutes only a small portion of all AD patients (younger than 65 years)(93).
Both familial and sporadic AD, Aβ peptide, a cleavage product of Aβ precursor protein (APP)
that is due to ß and γ secretases, is a key factor in pathology of AD (92, 94).

iv. Moderate Ethanol Preconditioning

Our lab has shown that moderate ethanol preconditioning for 6 days has a
neuroprotective effect against Aβ on in vitro model. Preconditioning refers to the phenomenon
that a sub-lethal, brief stress leads to protection against subsequent, normally lethal injury.
Moderate ethanol preconditioning (MEP; 20-30 mM) for 6 days protects rat cerebellar and
hippocampal cultures from neurotoxins such as Aβ. The neuroprotective mechanism of ethanol
is unclear, but it conceivably involves sensors→ transducers→ effectors, analogous to other
preconditioning modalities.
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v. Mechanism of MEP Protection and Peroxiredoxin

Peroxiredoxins (Prxs) are family of cytoplasmic anti apoptotic and anti oxidative
enzyme that catalyze the reduction of peroxides (92, 93). Family members possess a redox
active peroxidative cysteine sulfenic acid (-SOH). This oxidized form of PRX must then
reduced to the –SH Form by reduced Thioredoxin (Trx) (92, 93). Prx2 is expressed exclusively
in neurons of cerebral cortex, cerebellum, basal ganglia, substantia nigra and spinal cord (94).
Overexpression of Prx2 protects primary neurons against Aβ toxicity (95). In other brain
preconditioning models, Peroxiredoxin 2 overexpression protects cortical neuronal cultures
from ischemic and oxidative injury (96). The PRX2 level was detected in cell lysates by
Western blot using an anti-PRX2 antibody.

CHAPTER TWO
HYPOTHESIS AND SPECIFIC AIMS
I hypothesize that combination of non-protective level of resveratrol with non-protective
level of ethanol have synergistic protective effect to protect rat brain culture against Aβ
neurotoxicity. For reaching this goal, the overall project is broken down into five specific aims.
i. Aim I is to determine whether a shorter duration of MEP can protect cerebellar mixed cell
cultures against Aβ. To accomplish this aim I will carry out time course study of MEP to find
the duration for neuroprotection. The percent of dead cells will be counted in Hoechst 33342
stained cerebellar mixed cell cultures after 3 and 6 days of MEP and one day of exposure to Aβ.
ii. Aim II is to determine a non-protective level of ethanol in the 3 days of MEP. The cerebellar
mixed cell cultures be treated with different level of ethanol 30, 20, 10 mM for 3 days and one
day of exposure to Aβ, and the percent of dead cell will be counted in Hoechst 33342 stained
treated cell cultures and compared with control cell culture not treated with MEP.
iii. Aim III is to determine a non-protective of resveratrol. Cerebellar mixed cell cultures will
be treated with different concentrations of resveratrol 2, 5, 10 and 25 μM for 3 days and then
one more day of exposure to Aβ. The effects of treatment with different concentrations of
resveratrol were measured determining the percent of dead cells in Hoechst 33342 stained in
treated cell cultures.
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iv.

Aim IV is to determine a synergistic effect of non-protective levels of both ethanol and

resveratrol to protect against Aβ toxicity. Cerebellar mixed cell cultures were treated with both
5μM of resveratrol and 10mM ethanol for 3 days and then one day of exposure to Aβ. The dead
cells were counted in Hoechst33342 stained cell cultures and compared to counts in control cell
cultures.
v.

Aim V is to determine if peroxiredoxin 2 is involved in the synergistic effect of non-

protective levels of ethanol and resveratrol co-treatment pathway. Our lab has shown
Peroxiredoxin 2 increased significantly after 6 days of MEP. Co-treated cell cultures with 5μM
resveratrol and 10mM ethanol will be harvested and amount of peroxiredixin2 protein measured
by western blotting. To accomplish this aim, three groups of cultures on 10th day in vitro treated
with 10 mM ethanol, 5μM resveratrol and or the combination of 10mM ethanol and 5μM
resveratrol for 3 days. Another group of cultures were kept untreated as control group for 3
days.

CHAPTER THREE
MATERIALS AND METHODS

Chemical reagents and antibodies

Neurobasal–A media, B27, trypsin and fetal bovine serum (FBS) were from
Gibcoco. (Corlsbad, CA). Hoechst 33342, deoxyribonuclease I (DNAse),tweener 20,
protease and phosphatase inhibitor cocktails, and penicillin/streptomycin were provided
by Sigma Co. (St. Louis MO). Aβ 25-35 was from AmericanPeptide Co. (Sunnyvale,
CA). Polyacrylamide gels and Western blot enhanced chemiluminescence detection
(ECL) solutions were from Thermo scientist (Rockford, IL). The peroxiredoxin
antibodies (1:1000-10000) provided from Epitomics (Burlingame, CA), and the goat anti
rabbit antibodies (1:20000) were from Santa Cruz Co (Santa Cruz, CA), and actin anti
rabbit IgG (1:1000-20000) was from Cell Signaling (Danvers, MA).
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Cerebellar mixed primary cell cultures

Sprague-Dawley rat pups (7-10 days old) were anesthetized in co 2 chamber for 30
seconds and then rapidly decapitated. The brain was carefully removed and placed in icecold Gays balanced salt solution (GBSS) supplemented with 4.5mg/ml glucose. The
cerebellum was taken and placed into ice-cold MEM supplement with 6.5mg/ml glucose.
Meninges were removed, and the cerebellas were divided into approximately 6 pieces
each. Pieces were transferred into calcium/magnesium-free Hanks balanced salt solution
(CM-HBSS) containing 0.25% trypsin and 0.5 mg/ml DNAse at 37C. Tissue were
incubated for 10 min, and then transferred into MEM with 10% fetal bovine serum (FBS)
and 5% horse serum (HS) to inactivate trypsin. Cells were dispersed by triturating with
two fire polished pipettes that had decreasing size. Cells were then passed through a
70µm cell strainer. Viable cell density was determined by trypan blue exclusion on a
hemocytometer: cells were diluted to a concentration of 800000 cells/ml in 10% fetal
bovine serum in Neurobasal-A media supplemented with 2% B27 (Gibco), 500µg Lglutamine and 1% Penicillin-streptomycin. Then cells were plated on poly-l lysine coated
12 well plates at 700µl /well. Half of the media was changed after 24-36 hours, and then
every 3 days half of the media was replaced with serum-free Neurobasal-A media
supplemented with 2% B27 (Gibco), 500µg L-glutamine and 1% Penicillinstreptomycin. At DIV10 100% of media was changed.
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Preconditioning methods

At DIV 10, the cell cultures were placed in plastic Tupperware container with
different concentrations of ethanol in the media (30mM=MEP30, 20mM=MEP20,
10mM=LEP10, 5mM=LEP5) or ethanol free media for 3 or 6 days (100% serum free
media). A small open container containing 90, 60, 30,15 mM ethanol and 50 ml of double
distilled water were placed in the Tupperware container with the ethanol-treated cultures
to prevent loss of ethanol due to evaporation from the cultures. Control plates were
treated with the same method, but water was added to media and small container instead
of ethanol. The container was kept 10 min open to equilibrate with incubator and then
sealed for 3 or 6 days.
For resveratrol preconditioning, at DIV 10 different amounts of resveratrol (RES)
25, 10, 5 and 2 µM was added to 100% serum free cell media for 3 days.
For the combined preconditioning with resveratrol and ethanol, at DIV 10 Plates
were placed in the Tupperware container and treated with a combination of nonprotective level of ethanol and resveratrol (5 μM of resveratrol and 10 mM of
ethanol)(LEP10+RES5) in 100% serum free media for 3 days. A small open container
containing 30mM ethanol and 50 ml of double distilled water were placed in Tupperware
containing ethanol-treated cultures to prevent loss of ethanol due to evaporation from the
cultures. Control plates were treated with the same method, but water was added to the
media and small container instead of ethanol. The container was kept open for 10 min to
equilibrate with the incubator and then sealed for 3 days.
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At the end of pretreatment the media were completely changed to media
contained 25µM/ml of Aβ 25-35. This media was added in to the cultures except the control
group cultures.
For measuring cytotoxicity, the plates were incubated with 4% paraformaldehide
for 20 min, washed with iced-cold PBS, incubated with 100% methanol for 20 min, and
then with 2µl Hoechst 33342 stain stock solution in one ml of PBS for 20 min. The
picture of fixed and stained plates were taken with a Nikon fluorescent microscope. Five
pictures per well from predetermined areas (top right and left, central and bottom right
and left were taken). Live cells with faintly stained nuclei and dead cells with intensely
stained nuclei were easily recognized. For consistency in counting, cells that were cut by
the edge or corners of pictures or clusters of cells were not counted. The mean value,
standard deviation, and standard error of dead and live cells per each well are calculated
by excel program after adding the numbers of each picture. The final numbers are
obtained by taking the mean of mean value per picture, and standard deviation and
standard error of dead and live cells per each well of each dish were calculated and
analyzed by JBstat program for statistical analysis.

Cell fraction

The cell cultures were washed with iced-cold PBS, lysed in lysis buffer (20mM
Tris-HCl, PH 7.5, 5mM EDTA, 10µl/ml phosphatase inhibitor cocktail), homogenized by
sonication on a 550 Sonic Dismembator (Fisher Scientific; Pittsgurgh, PA) for 7 pulses,
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and spun in a microcentrifuge for 5 minutes at 1000 rpm and 4oC. The supernatant was
collected, and 25 µg of protein (measured by protein asssey) was used for western blot
analysis.

Measurement of protein

Protein was measured by using the bicinchoninic Acid (BCA) protein assay
(Pierce Rockford IL). Aliquots (25µl) were collected and added to individual wells of a
96-well plate. Each sample was incubated with 200 µl of the BCA reagent for 30 minutes
at 37oC. The absorbance of each sample was measured spetrophotometrically at 625 nm.
The protein levels of samples were calculating by calibrating the absorbance of the
individual samples with a standard curve generated with known concentrations of bovine
serum albumin (BSA).

Western blotting

25µg/well of samples were electrophoresed on 10%SDS-PAGE gel with constant
voltage at 120V for ~ 60 mins. The separated proteins were transferred to nitrocellulose
membranes by electrical current and then blocked for 1 hour with 5% milk solution. The
membrane was incubated overnight at 4oC with 1µl/ml of rabbit IgG anti-peroxiredoxin-2
for detection of peroxiredoxin-2 proteins and then washed 3 times with TBST followed
by incubation for 1 hour with secondary antibody. The loaded samples were probed with
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anti-GAPDH antibodyfor detection of GAPDH as a loading control. The proteins were
detected by using the Pierce super signal West pico detection kit and detected with X-ray
film. Western blots were quantified using NIH image software. The values of the band
intensities were normalized with GAPDH standards. The levels of peroxiredoxin2 of
treated cultures were compared with those of untreated control cultures.

Statistics

Each experiment was done 3-4 times. For experiments with Hoechst 33342
staining the number per group was 8-12 and for experiments with western blot the
numbers per group was 3-4.
The data were analyzed by one-way ANOVA with Tukey-Kramer post-hoc tests
for multiple comparisons between pairs. For experiments with two groups the means of
data were analyzed by independent sample t tests. P<0.05 was considered significant the
western blotting data for Peroxiredoxin-2 were analyzed by mixed effects ANOVA
followed by post-hoc Tukey-Kramer tests.

CHAPTER IV
RESULTS
i. AIM I: MEP for 3 days blocks Aβ toxicity in cerebellar mixed cell cultures
Figure 1 illustrates the percentage of dead cells in the four different groups:
Control for 6 days (CON6) and control for 6 days with 24 hours of Aβ toxicity
(CON6+Aβ), MEP for 6 days (MEP6), and MEP for 6 days followed by 24 hours of Aβ
exposure (MEP6+Aβ).
Figure 2 shows a representative picture of each group, to demonstrate the effect of
6 days of MEP on cerebellar mixed cell cultures.
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Figure 1: Quantification Hoechst 33342 staining on dead cells of cerebellar mixed
cell cultures. The experiment was done 3 times and result from representative
experiment is shown. Data represented as mean + S.E.M.N=8 and the ** shows the
p<0.001(CON6+Aβ VS CON6 or MEP6), which indicates Aβ toxicity and * depicts
p<0.05. (CON6+Aβ VS MEP6+Aβ).
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Figure 2: Demonstrates the effect of 6 days of MEP on cerebellar mixed cell
cultures. The four pictures were taken by fluorescent microscope from each well of
treated cell cultures.
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Figure 3 illustrates the percentage of dead cells in the four different groups:
Control for 3 days (CON3) and control for 3 days with 24 hours of Aβ toxicity
(CON3+Aβ) and MEP for 3 days (MEP3) and MEP for 3 days followed by 24 hours of
Aβ exposure (MEP3+Aβ).
Figure 4 shows a representative picture of each group; demonstrate the effect of 3 days of
MEP on cerebellar mixed cell cultures.
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Figure 3: Quantification Hoechst 33342 staining on dead cells of cerebellar mixed
cell cultures. The experiment was done 3 times and result from representative
experiment is shown. Data represented as mean + S.E.M.N=8 and the ** shows the
p<0.001(CON3+Aβ VS CON3 or MEP3), which indicates Aβ toxicity and * depicts
p<0.05 (CON3+Aβ VS MEP3+Aβ).
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Figure 4: Demonstrates the effect of 3 days of MEP on cerebellar mixed cell
cultures. The four pictures were taken by fluorescent microscope from each well of
treated cell cultures.
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ii. Aim II: determine the sub-protective level of ethanol

The purpose of this aim was to find the non-protective level of ethanol against Aβ
toxicity in cerebellar mixed cell cultures. Figure 5 shows a effect of different
concentrations of ethanol .The results of one-way ANOVA showed that there were
significant differences between the numbers of dead cells in the control group and the
groups of cells treated with Aβ and 10 or 5 mM ethanol, but there was no significant
difference in the number of dead cells between the control group and the group of cells
treated with Aβ and 20 mM ethanol (Fig 5). Aβ toxicity was verified by comparing the
number of dead cells between control cultures and the cultures were incubated with Aβ
for 24 hours. The one- way ANOVA results indicated the significant difference in
number of dead cells between two compared groups (Fig5). Figure 6 shows a
representative picture of each group, which is shown in figure 5. Based on the LEP 10
group (10mM ethanol) was chosen as the sub-protective level.
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Figure 5: 20 mM ethanol confers neuroprotection against Aβ toxicity in cerebellar
mixed cell cultures. The experiment was done 3 times and the result from representative
experiment is shown. Data represented as mean+S.E.M. p<0.05 was considered the
threshold for significance. ** P<0.001 (CON+ Aβ vs CON and MEP20+Aβ). N=8
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Figure 6: Demonstrates the effect of different concentration of ethanol on cerebellar
mixed cell cultures. 12 well dishes were used for cerebellar mixed cell cultures. The red
arrows point to dead cells. The pictures represent here are one of the sixty pictures per each
group of cell cultures.
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iii. Aim III: Determine the protective and sub-protective levels of resveratrol in
cerebellar mixed cell cultures against Aβ 25-35 toxicity.

The goal of this aim was to find the non-protective level of resveratrol against Aβ
induced cell death in cerebellar mixed cell cultures. As shown in Figure 7, cultures
treated with 25, 5 and 2 µM of resveratrol and incubated with Aβ 25-35 for 24 hours did
not show a significant decrease in the percentage of dead cells compared to the control
cultures treated with Aβ (CON+Aβ), while cultures treated with 10 µM resveratrol and
incubated with Aβ 25-35 did show a significantly decreased in percentage of dead cells
(Fig. 7). Aβ 25-35 toxicity was established in cerebellar mixed cell cultures by comparing
the percentage of dead cells to total number of cells in the control (CON) to the
control+Aβ group (CON+Aβ). The percentage of dead cells was significantly increased
in control+ Aβ group by one-way ANOVA (Fig. 7).
Figure 8 illustrates a picture of each group of figure 7, which presents an effect of
different concentrations of resveratrol on cerebellar mixed cell cultures. Based on the
RP5 method, 5μM resveratrol was chosen as the sub-protective level.
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Figure 7: protective effects of resveratrol against Aβ 25-35 toxicity in cerebellar
mixed cell cultures. Cells (day 10 in vitro) were treated with resveratrol at various
concentrations for 3 days before the addition of Aβ 25-35 for 24 hours. The experiment was
done three times and data from a representative experiment is shown. Data represented as
mean+S.E.M. p< 0.05 was considered the threshold for significance. * P<0.05(CON+Aβ
vs RP5+Aβ), ** P<0.001 (CON+Aβ vs RP10+Aβ). N=12
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Figure 8: Demonstrates the effect of different concentration of resveratrol on
cerebellar mixed cell cultures. 12 well dishes were used for cerebellar mixed cell
cultures. The red arrows point to dead cells. The pictures represent here are one out of the
sixty pictures per each group of cell cultures, which has been descried in Fig 7.

38
iv. Aim IV: Determine if co-treatment with non-protective levels of ethanol and
resveratrol blocks Aβ 25-35 induced cell death.

The objective of Aim IV was to examine the potential synergistic protective effect
of non-protective levels of ethanol and resveratrol against Aβ 25-35 toxicity. Based on the
result of aim II and III, 10 mM ethanol and 5 µM resveratrol were chosen as the subprotective levels. To investigate the synergistic effect, five groups of cerebellar mixed
cell cultures were treated on the 10th day in vitro. There were two untreated cell cultures;
one of them was exposed for 24 hours with Aβ 25-35 to establish Aβ 25-35 induced toxicity
(CON and CON+Aß). The remaining of three cell cultures was treated with 5 µM
resveratrol alone (RP5), 10 mM ethanol alone (LEP10) and the combination of 10 mM
ethanol and 5 µM resveratrol (LEP10+RP5). All pretreated cell cultures were exposed for
24 hours to Aβ 25-35 . The cultures were then fixed and stained by Hoechst 33342.
Five random pictures were taken from each well of dishes by florescent
microscopy, and the mean percentage of dead cells to total cells was calculated for each
group. A one-way ANOVA analysis revealed that the number of dead cells increased
significantly in Aβ 25-35 added to the untreated cell cultures compares to the untreated
group (Fig 9), It also showed a significantly increased number of dead cells in cell
cultures with non-protective concentrations of ethanol alone or resveratrol alone in cell
medium (Fig 9). Changes in cell morphology were assessed by florescent microscopic
examination (Fig 10). Exposure of cells to Aβ 25-35 at 10mM ethanol or 5µm resveratrol or
without any thing in cell medium resulted in more cell death than untreated cell cultures
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(Fig 10). However, the combined treatment with 10mM ethanol and 5μM resveratrol
provide significantly reduced Aβ toxicity.
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Figure 9: synergistic effect of non-protective level of ethanol and resveratrol confers
neuroprotection against Aβ toxicity in cerebellar mixed cell cultures. The experiment was
done 3 times and the result from representative experiment is shown. Data represented as
mean+S.E.M. p<0.05 was considered the threshold for significance. ** P<0.001 (CON+Aβ VS
CON and LEP10+RP5+Aβ). N=12
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Figure 10: Demonstrates the synergistic effect of non-protective level of ethanol and
on cerebellar mixed cell cultures. 12 well dishes were used for cerebellar mixed cell
cultures and the treated cells were fixed and stained with 33342 Hoechst stain. The red
arrows point to dead cells. The pictures represent here are one of the sixty pictures per
each group of cell cultures.
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v. Aim V: Determine the synergistic effect of non-protective concentration of ethanol and
resveratrol induces the expression of peroxiredoxin 2(PRX2).

The purpose of this Aim was to find out if the synergistic protective effect of
combined non-protective concentrations of ethanol and resveratrol alone induces the
expression of peroxiredoxin 2 in cerebellar mixed cell cultures. The results revealed that
cerebellar mixed cell cultures, treated by combined non-protective level of ethanol and
resveratrol showed increased level of PRX2 (Fig 10). Figure 10 represent the nonprotective levels of ethanol or resveratrol alone did not induce the expression of PRX2.
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Figure11: Level of PRX2 in cerebellar mixed cell cultures after 3 days treatment
with non-protective level of either ethanol or resveratrol and combination of them.
Results are the mean+S.E.M of two independent experiments. ** p<0.001 vs. control,
N=8

CHAPTER V
DISCUSSION

Our Lab has established the neuroprotective effect of moderate ethanol (30mM)
preconditioning against Aβ 25-35 induced cell toxicity in cerebellar mixed cell cultures
(Collins MA et al 2010). However the legal blood alcohol level in US is 80milligrams in
100 milliliter of blood, which is equal to 17.3 mM of ethanol. Three to four glasses of
wine (5 fluid ounces of wine is one unite are needed to increase the alcohol blood level
up to 0.08. To reaching the protective level of alcohol based on our lab studies it would
be necessary to drink six glasses of wine.
It has shown that after on oral dose of 25mg (110 µM) of resveratrol the plasma
concentration reached about 2µM after 1 hour (walle et.al 2004). However the protective
dose of resveratrol against Aß

25-35

in hippocampal neural cell cultures is 25 µM, more

than 10 times the oral dose (Han et.al 2004). To reach a 25µM resveratrol in plasma
based of low resveratrol bioavailability a 312mg oral dose of resveratrol should be taken,
which is amount of resveratrol in 24 liters of wine (highest amount of resveratrol in wine
is 13mg/liter)!
The present study has shown that the combinatory effect of ethanol and
resveratrol reduced the protective levels of either ethanol or resveratrol alone. 10mM
ethanol combined with 5µM resveratrol blocked the
44

Aß 25-35 toxicity. About two glasses
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of wine (10 fluid ounce) can provide 10mM ethanol and almost 5 liter of wine can
provide 5µM resveratrol in plasma.
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